Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisParis, December 24, 2025.

Researchers have found a new link between exposure to ‘forever chemicals’ and one lifelong health condition. A Sweden-based ...

Sanofi will conduct an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026.

MS relapses are more common in spring and summer, coinciding with warmer, drier weather and atmospheric changes, a study ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis: Paris Friday, December 26, 2025, 13:00 Hrs [IST] The US Foo ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

Jamie-Lynn Sigler is returning to TV after a three-year break to play a Grey's Anatomy doctor with multiple sclerosis. “If you told me 20 years ago that I would play a role on one of my favorite shows ...

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regu ...

Researchers at Oregon Health & Science University have identified a type of enzyme with a complicated name — cell migration inducing and hyaluronan-binding protein, or CEMIP — is associated with ...

Explore the relationship between gluten intolerance and Multiple Sclerosis (MS). Learn what the research says, possible links ...